{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:38:18Z","timestamp":1793446698595,"version":"4.5.0"},"reference-count":114,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grants-in-Aid for Scientific Research, Japan","award":["20K09553"],"award-info":[{"award-number":["20K09553"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>A recent approach to radiotherapy for prostate cancer is the administration of high doses of radiation to the prostate while minimizing the risk of side effects. Thus, image-guided radiotherapy utilizes advanced imaging techniques and is a feasible strategy for increasing the radiation dose. New radioactive particles are another approach to achieving high doses and safe procedures. Prostate brachytherapy is currently considered as a combination therapy. Spacers are useful to protect adjacent organs, specifically the rectum, from excessive radiation exposure.<\/jats:p>","DOI":"10.3390\/curroncol30090587","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T09:24:53Z","timestamp":1693560293000},"page":"8092-8110","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5899-1738","authenticated-orcid":false,"given":"Kazuyuki","family":"Numakura","sequence":"first","affiliation":[{"name":"Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumina","family":"Muto","sequence":"additional","affiliation":[{"name":"Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Sekine","sequence":"additional","affiliation":[{"name":"Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Sobu","sequence":"additional","affiliation":[{"name":"Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Aoyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syuhei","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Sasagawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2988-1860","authenticated-orcid":false,"given":"Shintaro","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kumagai","sequence":"additional","affiliation":[{"name":"Department of Radiology, Akita University Graduate School of Medicine, Akita 010-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2013-7413","authenticated-orcid":false,"given":"Yuki","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Radiology, Akita University Graduate School of Medicine, Akita 010-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8700-9731","authenticated-orcid":false,"given":"Naoko","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Radiology, Akita University Graduate School of Medicine, Akita 010-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Habuchi","sequence":"additional","affiliation":[{"name":"Department of Urology, Akita University Graduate School of Medicine, Akita 010-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41585-021-00498-6","article-title":"Practical considerations for prostate hypofractionation in the developing world","volume":"18","author":"Yan","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eururo.2015.11.010","article-title":"Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis","volume":"70","author":"Wallis","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2022.11.002","article-title":"Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-\/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022","volume":"83","author":"Gillessen","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1200\/JCO.1997.15.3.1013","article-title":"Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31","volume":"15","author":"Pilepich","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","article-title":"Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial","volume":"378","author":"Warde","year":"2011","journal-title":"Lancet"},{"key":"ref_8","first-page":"8728","article-title":"Robotic prostatectomy versus brachytherapy for the treatment of low risk prostate cancer","volume":"24","author":"Giberti","year":"2017","journal-title":"Can. J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijrobp.2010.05.056","article-title":"Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05)","volume":"81","author":"Lawton","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1200\/JCO.2014.57.7510","article-title":"Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer","volume":"33","author":"Mason","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijrobp.2006.08.056","article-title":"Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation","volume":"67","author":"Zelefsky","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1159\/000322507","article-title":"Stereotactic body radiotherapy for prostate cancer: Current results of a phase II trial","volume":"43","author":"King","year":"2011","journal-title":"Front. Radiat. Ther. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1074540","DOI":"10.3389\/fendo.2022.1074540","article-title":"Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.juro.2015.11.005","article-title":"Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base","volume":"195","author":"Amini","year":"2016","journal-title":"J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrurol.2017.76","article-title":"The evolution of brachytherapy for prostate cancer","volume":"14","author":"Zaorsky","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11547-023-01618-5","article-title":"Extreme hypofractionated stereotactic radiotherapy for elderly prostate cancer patients: Side effects preliminary analysis of a phase II trial","volume":"128","author":"Gregucci","year":"2023","journal-title":"Radiol. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3389\/fonc.2019.01273","article-title":"Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions","volume":"9","author":"Greenberger","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2003.11.023","article-title":"Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02","volume":"21","author":"Hanks","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","article-title":"Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer","volume":"98","author":"Morris","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","article-title":"Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results","volume":"154","author":"Hoskin","year":"2021","journal-title":"Radiother. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12957-020-01824-9","article-title":"The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: A systematic review and meta-analysis","volume":"18","author":"Wang","year":"2020","journal-title":"World J. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Burgess, L., Roy, S., Morgan, S., and Malone, S. (2021). A Review on the Current Treatment Paradigm in High-Risk Prostate Cancer. Cancers, 13.","DOI":"10.3390\/cancers13174257"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1200\/JCO.19.03217","article-title":"Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials","volume":"38","author":"Jackson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrurol.2013.185","article-title":"Evolution of advanced technologies in prostate cancer radiotherapy","volume":"10","author":"Zaorsky","year":"2013","journal-title":"Nat. Rev. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1056\/NEJMsa1201141","article-title":"Urologists\u2019 use of intensity-modulated radiation therapy for prostate cancer","volume":"369","author":"Mitchell","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1118\/1.1591194","article-title":"Guidance document on delivery, treatment planning, and clinical implementation of IMRT: Report of the IMRT Subcommittee of the AAPM Radiation Therapy Committee","volume":"30","author":"Ezzell","year":"2003","journal-title":"Med. Phys."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yu, T., Zhang, Q., Zheng, T., Shi, H., Liu, Y., Feng, S., Hao, M., Ye, L., Wu, X., and Yang, C. (2016). The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154499"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e180039","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of Standard vs Dose-Escalated Radiation Therapy for Patients with Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijrobp.2021.07.004","article-title":"Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG\/RTOG 0126","volume":"112","author":"Hall","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.29983","article-title":"Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial","volume":"122","author":"Viani","year":"2016","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): Final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Late toxicity results from a randomised, non-inferiority, phase 3 trial","volume":"17","author":"Aluwini","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S1470-2045(15)00280-6","article-title":"Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"16","author":"Wilkins","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14470","article-title":"Intensity-modulated radiotherapy for the treatment of prostate cancer: A systematic review and economic evaluation","volume":"14","author":"Hummel","year":"2010","journal-title":"Health Technol. Assess."},{"key":"ref_38","first-page":"705604","article-title":"Image guidance in radiation therapy: Techniques and applications","volume":"2014","author":"Goyal","year":"2014","journal-title":"Radiol. Res. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ijrobp.2011.08.025","article-title":"Adaptive image-guided radiotherapy (IGRT) eliminates the risk of biochemical failure caused by the bias of rectal distension in prostate cancer treatment planning: Clinical evidence","volume":"83","author":"Park","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_40","first-page":"81","article-title":"The role of image-guided radiotherapy in prostate cancer: A systematic review and meta-analysis","volume":"38","author":"Wang","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.rpor.2016.01.005","article-title":"Reducing radiation-associated toxicity using online image guidance (IGRT) in prostate cancer patients undergoing dose-escalated radiation therapy","volume":"21","author":"Abaci","year":"2016","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijrobp.2008.08.055","article-title":"Commissioning of volumetric modulated arc therapy (VMAT)","volume":"73","author":"Bedford","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"R343","DOI":"10.1088\/0031-9155\/51\/13\/R20","article-title":"Back to the future: The history and development of the clinical linear accelerator","volume":"51","author":"Thwaites","year":"2006","journal-title":"Phys. Med. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2018.07.003","article-title":"Optimal scheduling of hypofractionated radiotherapy for localized prostate cancer: A systematic review and metanalysis of randomized clinical trials","volume":"70","author":"Arcangeli","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.radonc.2022.06.014","article-title":"Cost-effectiveness of hypofractionated versus conventional radiotherapy in patients with intermediate-risk prostate cancer: An ancillary study of the PROstate fractionated irradiation trial\u2014PROFIT","volume":"173","author":"Zhou","year":"2022","journal-title":"Radiother. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1259\/bjr\/22373346","article-title":"Volumetric modulated arc therapy: A review of current literature and clinical use in practice","volume":"84","author":"Teoh","year":"2011","journal-title":"Br. J. Radiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"20201289","DOI":"10.1259\/bjr.20201289","article-title":"Volumetric modulated arc therapy (VMAT): A review of clinical outcomes-what is the clinical evidence for the most effective implementation?","volume":"95","author":"Hunte","year":"2022","journal-title":"Br. J. Radiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.3390\/curroncol28040257","article-title":"Extreme Hypofractionation with SBRT in Localized Prostate Cancer","volume":"28","author":"Valero","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fonc.2017.00185","article-title":"Propensity Score Matched Comparison of Intensity Modulated Radiation Therapy vs Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Survival Analysis from the National Cancer Database","volume":"7","author":"Ricco","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13014-023-02233-4","article-title":"Stereotactic body radiation therapy for prostate cancer: A study comparing 3-year genitourinary toxicity between CyberKnife and volumetric-modulated arc therapy by propensity score analysis","volume":"18","author":"Ito","year":"2023","journal-title":"Radiat. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1538-4721(02)00101-0","article-title":"LDR vs. HDR brachytherapy for localized prostate cancer: The view from radiobiological models","volume":"1","author":"King","year":"2002","journal-title":"Brachytherapy"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.brachy.2021.07.006","article-title":"Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement","volume":"20","author":"King","year":"2021","journal-title":"Brachytherapy"},{"key":"ref_56","first-page":"531","article-title":"Brachytherapy with permanent seed implantation","volume":"74","author":"Saito","year":"2016","journal-title":"Nihon Rinsho"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1464-410X.2009.09096.x","article-title":"Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants","volume":"106","author":"Prada","year":"2010","journal-title":"BJU Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ijrobp.2016.06.026","article-title":"Initial Report of NRG Oncology\/RTOG 0232: A Phase 3 Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate-Risk Prostatic Carcinoma","volume":"96","author":"Prestidge","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semradonc.2019.08.002","article-title":"Progress in Low Dose Rate Brachytherapy for Prostate Cancer","volume":"30","author":"McLaughlin","year":"2020","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Kissel, M., Crehange, G., and Graff, P. (2022). Stereotactic Radiation Therapy versus Brachytherapy: Relative Strengths of Two Highly Efficient Options for the Treatment of Localized Prostate Cancer. Cancers, 14.","DOI":"10.3390\/cancers14092226"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"357","DOI":"10.21037\/tau.2017.12.08","article-title":"High dose-rate brachytherapy in the treatment of prostate cancer","volume":"7","author":"Mendez","year":"2018","journal-title":"Transl. Androl. Urol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5114\/jcb.2021.108590","article-title":"High-dose-rate fractionated brachytherapy monotherapy for localized prostate cancer: A systematic review and meta-analysis","volume":"13","author":"Anderson","year":"2021","journal-title":"J. Contemp. Brachyther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.radonc.2020.02.009","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy","volume":"146","author":"Morton","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.brachy.2010.10.002","article-title":"Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy","volume":"10","author":"Carpenter","year":"2011","journal-title":"Brachytherapy"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.brachy.2011.01.004","article-title":"Predictors of the use of supplemental androgen suppression therapy and external beam radiation in men with high-risk prostate cancer undergoing brachytherapy in community practice","volume":"10","author":"Hattangadi","year":"2011","journal-title":"Brachytherapy"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.11.005","article-title":"An Updated Analysis of the Survival Endpoints of ASCENDE-RT","volume":"115","author":"Oh","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Konaka, H., Egawa, S., Saito, S., Yorozu, A., Takahashi, H., Miyakoda, K., Fukushima, M., Dokiya, T., Yamanaka, H., and Stone, N.N. (2012). Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): Study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-110"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40001-022-00942-2","article-title":"Does particle radiation have superior radiobiological advantages for prostate cancer cells? A systematic review of in vitro studies","volume":"27","author":"Du","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14338\/IJPT-20-00031.1","article-title":"Consensus Statement on Proton Therapy for Prostate Cancer","volume":"8","author":"Bryant","year":"2021","journal-title":"Int. J. Part. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Poon, D.M.C., Wu, S., Ho, L., Cheung, K.Y., and Yu, B. (2022). Proton Therapy for Prostate Cancer: Challenges and Opportunities. Cancers, 14.","DOI":"10.3390\/cancers14040925"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"760752","DOI":"10.3389\/fonc.2021.760752","article-title":"Landscape of Carbon Ion Radiotherapy in Prostate Cancer: Clinical Application and Translational Research","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/iju.14102","article-title":"Quality of life in prostate cancer patients receiving particle radiotherapy: A review of the literature","volume":"27","author":"Kawamura","year":"2020","journal-title":"Int. J. Urol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.radonc.2016.10.009","article-title":"A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: A report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS)","volume":"121","author":"Nomiya","year":"2016","journal-title":"Radiother. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"709530","DOI":"10.3389\/fonc.2021.709530","article-title":"Clinical Efficacy and Safety of Proton and Carbon Ion Radiotherapy for Prostate Cancer: A Systematic Review and Meta-Analysis","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3322\/CA.2008.0002","article-title":"Management of complications of prostate cancer treatment","volume":"58","author":"Michaelson","year":"2008","journal-title":"CA Cancer J. Clin."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.ejca.2009.07.009","article-title":"Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991","volume":"45","author":"Matzinger","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.21037\/tcr-20-2589","article-title":"Urological complications after radiation therapy-nothing ventured, nothing gained: A Narrative Review","volume":"10","author":"Chorbinska","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.juro.2016.08.101","article-title":"Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment","volume":"197","author":"Chang","year":"2017","journal-title":"J. Urol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/ijcp.12693","article-title":"Integrative review on the non-invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies","volume":"69","author":"Faithfull","year":"2015","journal-title":"Int. J. Clin. Pract."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ijrobp.2009.05.052","article-title":"Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: Results from the UK Medical Research Council RT01 trial (ISRCTN47772397)","volume":"77","author":"Syndikus","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/EDBK_323525","article-title":"Management of Long-Term Toxicity From Pelvic Radiation Therapy","volume":"41","author":"Dalsania","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/bjc.2017.30","article-title":"Patients\u2019 perceptions of the negative effects following different prostate cancer treatments and the impact on psychological well-being: A nationwide survey","volume":"116","author":"Lehto","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1148\/radiology.217.1.r00oc24215","article-title":"Rectal bleeding after radiation therapy for prostate cancer: Endoscopic evaluation","volume":"217","author":"Moore","year":"2000","journal-title":"Radiology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"917941","DOI":"10.1155\/2011\/917941","article-title":"Radiation proctitis: Current strategies in management","volume":"2011","author":"Do","year":"2011","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.rpor.2020.03.011","article-title":"Prostatic irradiation-induced sexual dysfunction: A review and multidisciplinary guide to management in the radical radiotherapy era (Part I defining the organ at risk for sexual toxicities)","volume":"25","author":"Rogers","year":"2020","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0360-3016(95)00542-7","article-title":"Decreased sexual capacity after external radiation therapy for prostate cancer impairs quality of life","volume":"32","author":"Helgason","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1525-1497.2001.00832.x","article-title":"Sexuality after treatment for early prostate cancer: Exploring the meanings of \u201cerectile dysfunction\u201d","volume":"16","author":"Bokhour","year":"2001","journal-title":"J. Gen. Intern. Med."},{"key":"ref_89","first-page":"124","article-title":"Radiotherapy for prostate cancer and sexual health","volume":"4","author":"Incrocci","year":"2015","journal-title":"Transl. Androl. Urol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1001\/jama.2014.2626","article-title":"Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: The Radiation Therapy Oncology Group [0831] randomized clinical trial","volume":"311","author":"Pisansky","year":"2014","journal-title":"JAMA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/imj.12325","article-title":"Erectile dysfunction","volume":"44","author":"McMahon","year":"2014","journal-title":"Intern. Med. J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.adro.2016.05.003","article-title":"Radiation-induced erectile dysfunction: Recent advances and future directions","volume":"1","author":"Mahmood","year":"2016","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0885-3924(01)00361-X","article-title":"Fatigue in patients with cancers of the breast or prostate undergoing radical radiotherapy","volume":"22","author":"Stone","year":"2001","journal-title":"J. Pain. Symptom Manag."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fmolb.2014.00024","article-title":"Biological response of cancer cells to radiation treatment","volume":"1","author":"Baskar","year":"2014","journal-title":"Front. Mol. Biosci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.3747\/co.19.963","article-title":"Effects of radiation and total androgen blockade on serum hemoglobin, testosterone, and erythropoietin in patients with localized prostate cancer","volume":"19","author":"Golfam","year":"2012","journal-title":"Curr. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1158\/1078-0432.CCR-08-2584","article-title":"Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer","volume":"15","author":"Bower","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: Signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-022-01238-y","article-title":"Circadian rhythms and cancers: The intrinsic links and therapeutic potentials","volume":"15","author":"Zhou","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/23809000.2016.1191948","article-title":"The Etiology and management of radiotherapy-induced fatigue","volume":"1","author":"Hsiao","year":"2016","journal-title":"Expert. Rev. Qual. Life Cancer Care"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41391-021-00470-w","article-title":"Effects of yoga in men with prostate cancer on quality of life and immune response: A pilot randomized controlled trial","volume":"25","author":"Kaushik","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_101","first-page":"81","article-title":"Exercise Recommendations for Cancer-Related Fatigue, Cognitive Impairment, Sleep problems, Depression, Pain, Anxiety, and Physical Dysfunction: A Review","volume":"8","author":"Mustian","year":"2012","journal-title":"Oncol. Hematol. Rev."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Baguley, B.J., Bolam, K.A., Wright, O.R.L., and Skinner, T.L. (2017). The Effect of Nutrition Therapy and Exercise on Cancer-Related Fatigue and Quality of Life in Men with Prostate Cancer: A Systematic Review. Nutrients, 9.","DOI":"10.3390\/nu9091003"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1634\/theoncologist.2013-0076","article-title":"Aiming for a better understanding and management of cancer-related fatigue","volume":"18","author":"Neefjes","year":"2013","journal-title":"Oncologist"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","article-title":"Cancer-related fatigue--mechanisms, risk factors, and treatments","volume":"11","author":"Bower","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1188\/08.CJON.S2.21-25","article-title":"Management of cancer-related fatigue","volume":"12","author":"Barsevick","year":"2008","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.eururo.2007.07.002","article-title":"Secondary cancer after radiotherapy for prostate cancer: Should we be more aware of the risk?","volume":"52","author":"Bostrom","year":"2007","journal-title":"Eur. Urol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.brachy.2022.03.001","article-title":"Secondary bladder cancer during long-term follow-up after iodine-125 permanent seed implantation for localized prostate cancer","volume":"21","author":"Ozawa","year":"2022","journal-title":"Brachytherapy"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1756287210374462","article-title":"Secondary malignancies following radiotherapy for prostate cancer","volume":"2","author":"Sountoulides","year":"2010","journal-title":"Ther. Adv. Urol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"i851","DOI":"10.1136\/bmj.i851","article-title":"Second malignancies after radiotherapy for prostate cancer: Systematic review and meta-analysis","volume":"352","author":"Wallis","year":"2016","journal-title":"BMJ"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13014-016-0738-z","article-title":"Risk of second cancer following radiotherapy for prostate cancer: A population-based analysis","volume":"12","author":"Hegemann","year":"2017","journal-title":"Radiat. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jamaoncol.2023.1638","article-title":"Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002\u20132015","volume":"9","author":"Pithadia","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1016\/j.clon.2016.05.005","article-title":"SpaceOAR Hydrogel in Dose-escalated Prostate Cancer Radiotherapy: Rectal Dosimetry and Late Toxicity","volume":"28","author":"Whalley","year":"2016","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e208221","DOI":"10.1001\/jamanetworkopen.2020.8221","article-title":"Association of the Placement of a Perirectal Hydrogel Spacer with the Clinical Outcomes of Men Receiving Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis","volume":"3","author":"Miller","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-022-02197-x","article-title":"Hyaluronic acid spacer in prostate cancer radiotherapy: Dosimetric effects, spacer stability and long-term toxicity and PRO in a phase II study","volume":"18","author":"Bjoreland","year":"2023","journal-title":"Radiat. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/9\/587\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:44:33Z","timestamp":1760129073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/9\/587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":114,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["curroncol30090587"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30090587","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}